# Bempedoic Acid (Nexlizet)

Source: https://ourhealthnetwork.com/drugs/bempedoic-acid
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Bempedoic Acid?

Bempedoic Acid (brand name: Nexlizet) is an adenosine triphosphate-citrate lyase inhibitor. Across the United States, 1,000 doctors prescribe Bempedoic to approximately 2,000 Medicare patients.

## Brand names

Nexlizet

## Indications

NEXLIZET, a combination of bempedoic acid and ezetimibe, is indicated: as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Bempedoic acid, a component of NEXLIZET, is indicated: to reduce the risk of major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke, or coronary revascularization) in adults at increased risk for these events who are unable to take recommended st

## Conditions treated

- [Consult prescribing information](https://ourhealthnetwork.com/conditions/consult-prescribing-information)

## Mechanism of action

NEXLIZET contains bempedoic acid and ezetimibe. NEXLIZET reduces elevated LDL-C through inhibition of cholesterol synthesis in the liver and absorption in the intestine.

## Drug classification

- Established Pharmacologic Class: Adenosine Triphosphate-Citrate Lyase Inhibitor [EPC]
- Mechanism of Action class: Adenosine Triphosphate-Citrate Lyase Inhibitors [MoA]
- Route of administration: ORAL

## Common side effects

fatigue, sinusitis, upper respiratory tract infection

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)